In this article, the author discusses the circumstances under which the provision of benefits in kind to employees must be characterized as constituting a taxable supply for consideration, and the further consequences of such characterization, taking into account the ECJ’s decision in Astra Zeneca. The author also discusses the significant differences between taxing those benefits as normal supplies or as so-called deemed supplies.